

Genentech, Inc.

1 DNA WAY
South San Francisco, CA 94080
(650) 225-1000
Facsimile: (650) 952-9881

FACSIMILE TRANSMITTAL

DATE: January 11, 2005

RECEIVED
CENTRAL FAX CENTER

Please deliver the following page(s) to:

JAN 11 2005

NAME: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Fax No.. (571) 273-8300 and (571) 273-0706

FROM: David W Evans
Registration No.: *

RE: U.S. Serial No.: 10/676,706
Our Docket No.: P1845R1C2

Number of Pages including this cover sheet - 6

CERTIFICATION OF FACSIMILE TRANSMISSION UNDER 37 CFR § 1.8	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>Aida Guam</u> Type or print name of person signing certification	
Signature <u><i>Aida Guam</i></u>	Date: <u>1/11/2005</u>

CONFIDENTIAL NOTE

The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. The information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us and the retransmission of them to the intended recipient.

If you do not receive all pages, please notify Aida Guam at (650) 225-1732

Enclosed is a copy of the Terminal Disclaimer filed on 9/17/04 and the Auto-Reply Facsimile Transmission from the USPTO acknowledging receipt thereof.

* A copy of a document pursuant to 37 C.F.R. §10 9(b) is attached as proof of the authorization of the above to prosecute the attached application. The original of this document is on file in the Office of Enrollment and Discipline

Auto-Reply Facsimile Transmission



TO:

Fax Sender at +16509529881

Fax Information

Date Received:

Total Pages:

9/17/2004 11:13:57 PM [Eastern Daylight Time]
19 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page
=====>

SENDER	TO	FROM	DATE	PAGE	FAX
Genentech, Inc. 1 DNA WAY South San Francisco, CA 94080 (415) 353-1000 Facsimile: (415) 353-9081			FACSIMILE TRANSMITTAL		
DATE: September 17, 2004					
Please deliver the following page(s) to:					
NAME: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
Fax No: (703) 872-8308					
FROM: David W Evans Registration No.: *					
RE: U.S. Serial No.: 10/676,706 Our Document No.: P1845R1C2					
Number of Pages including the cover sheet: 19					
<div>CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that this paper is being transmitted to the Patent and Trademark Office on the date and time indicated. Print Name Type or print name of person making certification Signature: [Signature] Date: 9/17/2004</div>					
DISCLAIMER The information contained on this facsimile transmission is derived from Genentech, Inc., which is confidential or privileged. The information is intended only for the addressee or addressee named on the transmittal sheet. If you are not the intended recipient, do not disseminate, copy, or use of the contents of this facsimile transmission is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can advise the sender of the original document. We will not be responsible for the transmission of such information to the intended recipient.					
If you do not receive all pages, please notify Aida Gudim at (550) 225-1752					
Enclosed for consideration and entry on the record in connection with the above application are: this cover page; Amendment; Response; Petition for 1 Month Extension; and Terminal Disclaimer					
* A copy of a published document is 37 CFR 1.101.101 is required as proof of the submission of the above to preserve the claimed application. The original of this document is on file in the Office of Inventive and Disclosure					

PAGE 1/1 * RCVD AT 9/17/2004 11:13:57 PM [Eastern Daylight Time] * SVR:USPTO-EFAX-1/24 * DNIS:2738300 * CSID:+6509529882 * DURATION (mm:ss):01:46

Terminal
Disclaimer
Filed
9/17/04

RECEIVED
CENTRAL FAX CENTER

JAN 11 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Group Art Unit: 1626

Artis et al

Customer no.: 09157

Serial No.: 10/676,706

Conf. No.: 8143

Filed: 30 September 2003

Examiner: Shameem, Golam M

For: INTEGRIN RECEPTOR INHIBITORS

Certificate of Facsimile Transmission

I hereby certify that the correspondence is being filed with the United States Patent and Trademark Office addressed to: Commissioner for Patents, facsimile No. (703) 872-8307 on

17 September 2004


David W. Evans

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER A PRIOR PATENT**

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Your petitioner, Genentech, Inc., having a place of business at 1 DNA Way, South San Francisco, California 94080-4990 in the county of San Mateo has reviewed the evidentiary documents set forth hereinbelow and certifies to the best of Genentech's knowledge and belief that title in and to the herein application and in the referenced U.S. Patent No. 6,706,753 reside in Genentech, Inc.

10/676,706

Page No. 2

Your petitioner, Genentech, Inc., represents that it is the owner of the entire right, title, and interest in and to application U.S. Serial No. 10/676,706 filed September 30, 2003 by virtue of an assignment, and is also the owner of the entire right, title and interest in and to U.S. Patent No. 6,706,753 filed December 6, 2002 and issued March 16, 2004 by virtue of an assignment recorded on October 1, 2001 at reel/frame 012222/0432.

Your petitioner hereby disclaims the terminal part of any patent granted on the herein application Serial No. 10/676,706 that would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of said Patent No. 6,706,753 and hereby agrees that any patent so granted on the herein application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,706,753 this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of Patent No. 6,706,753 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above. Petitioner reserves the right to extend the shortened term of any patent granted on the above-identified application due to regulatory delays pursuant to 35 U.S.C. §156.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

10/676,706

Page No. 3

The Commissioner is authorized to charge the statutory fee of \$110 required for filing this Disclaimer to Deposit Account No. 07-0630. Please charge any deficiency or credit any overpayment to Account 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,
GENENTECH, INC.

Date: September 17, 2004

By:


David W. Evans

Reg. No. *

Telephone No. (650) 225-1739



09157

PATENT TRADEMARK OFFICE

*A copy of a document pursuant to 37 C.F.R. § 10.8(b) is attached as proof of the authorization of the above to prosecute the attached application. The original of this document is on file in the Office of Enrollment and Discipline.


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

David Evans is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Genentech, Inc. to prepare and prosecute patent applications in which Genentech, Inc. is the assignee of record of the entire interest. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) David Evans ceases to lawfully reside in the United States, (ii) David Evans' employment with Genentech, Inc. ceases or is terminated, or (iii) David Evans ceases to remain or reside in the United States on an H1B1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: April 6, 2005



Harry I. Moatz
Director of Enrollment and Discipline